Dr. Oh on Adapting the PRINT Trial Model to Other Settings in Prostate Cancer

Partner | Cancer Centers | <b>The Tisch Cancer Institute</b>

William K. Oh, MD, discusses adapting the phase 2 PRINT trial model to other settings in prostate cancer

William K. Oh, MD, chief of the Division of Hematology and Medical Oncology and professor of medicine and urology at Mount Sinai Hospital, as well as the deputy director of the Tisch Cancer Institute, discusses adapting the phase 2 PRINT trial model to other settings in prostate cancer.

The PRINT trial rapidly cycled non—cross reactive pairs of approved agents in patients with newly diagnosed metastatic castration-resistant prostate cancer to try to treat intrinsic heterogeneity, delay and prevent drug resistance, and minimize toxicity.

This model may be adapted to new drugs in mCRPC or different disease states and settings such as hormone-sensitive prostate cancer and neoadjuvant treatment, explains Oh.

It may take an extended period of time to fully understand the synergistic effect between 2 agents, says Oh.

As such, selecting 2 agents that can be safely administered together and testing them in different sequences may be the optimal approach to quickly gauge how drugs work together, concludes Oh.